SCHEMBL3006950

SCHEMBL3006950

COc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cc(C)c(Cl)cc4Cl)CC3)n2)c(OC)c1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.37
F2RL3 Q96RI0 7/20 0.36
LMNA P02545 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
RECQL P46063 2/20 0.35
ALDH1A1 P00352 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
FPR2 P25090 2/20 0.34
PROKR1 Q8TCW9 2/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
USP2 O75604 1/20 0.34
HSD17B10 Q99714 1/20 0.34
F2 P00734 1/20 0.34
KMT2A Q03164 1/20 0.34
TP53 P04637 1/20 0.34
TSHR P16473 1/20 0.34
CYP19A1 P11511 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014455 0.94 ALDH1A1 (0.37) MAPTF2RL3LMNATDP1RECQL
SCHEMBL3016184 0.90 SMN1; SMN2 (0.37) MAPTF2RL3LMNATDP1ALDH1A1
SCHEMBL3013303 0.90 MAPT (0.37) MAPTF2RL3LMNATDP1ALDH1A1
SCHEMBL3013781 0.90 TP53 (0.36) MAPTF2RL3LMNARECQLALDH1A1
SCHEMBL3013176 0.89 ALDH1A1 (0.45) MAPTLMNARECQLALDH1A1L3MBTL1
SCHEMBL3013852 0.89 CTSS (0.40) MAPTLMNATDP1ALDH1A1L3MBTL1
SCHEMBL3020081 0.88 RAB9A (0.38) MAPTF2RL3RECQLALDH1A1RAB9A
SCHEMBL3013075 0.88 MAPT (0.40) MAPTF2RL3LMNATDP1ALDH1A1
SCHEMBL3009127 0.88 CTSS (0.42) MAPTF2RL3LMNATDP1RECQL
SCHEMBL15671698 0.88 MAPT (0.36) MAPTF2RL3LMNATDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885F2RL3 3732/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.